METHYLENE BLUE FOR TREATMENT OF HOSPITALIZED COVID-19 PATIENTS: A RANDOMIZED, CONTROLLED, OPEN-LABEL CLINICAL TRIAL, PHASE 2

What Was Tested

The paper reports a study of Methylene blue (non-peptide stack partner), published as a randomized controlled trial.

Who Took Part

The abstract describes 19 patients taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

In an academic medical center, 80 hospitalized patients with severe COVID-19 were randomly assigned to receive either oral MB along with standard of care (SOC) (MB group, n = 40) or SOC only (SOC group, n=40).

How the Study Was Run

The design is described as randomized.

Because people in this Methylene blue (non-peptide stack partner) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The methods mention a period of 28 days.

The primary outcomes were SpO2 and RR on the 3rd and 5th days.

The secondary outcomes were hospital stay and mortality within 28 days.

What Was Measured

PubMed files the paper under topics including Hospitalization, Methylene Blue and COVID-19 Drug Treatment.

Author keywords: Hypoxemia and Mortality.

What This Means in Plain Language

The paper is a randomized study of Methylene blue (non-peptide stack partner) in 19 patients over 28 days.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.